UK-based Silence Therapeutics Plc has appointed Mark Rothera as president and chief executive officer to lead development of its prospective siRNA therapeutics. Mr Rothera joins Silence from Orchard Therapeutics Plc where he built the small biotech into a gene therapy company with seven clinical-stage programmes. Prior to this, he was chief commercial officer of PTC Therapeutics Inc, global president of Aegerion Pharmaceuticals Inc, and general manager of commercial operations at Shire Human Genetic Therapies for Europe, the Middle East and Africa. Mr Rothera received an MA in natural sciences from Cambridge University and an MBA from the European Institute for Business Administration (INSEAD).
Silence Therapeutics announced the appointment on 14 September 2020
Copyright 2020 Evernow Publishing Ltd